On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia

Leukemia

Volumn 22, Issue 9, 2008, Pages 1707-1711

  Feldman, E J ^a   Cortes, J ^b   DeAngelo, D J ^c   Holyoake, T ^d   Simonsson, B ^e   O'Brien, S G ^f   Reiffers, J ^g   Turner, A R ^h   Roboz, G J ^a   Lipton, J H ⁱ   Maloisel, F ^j   Colombat, P ^k   Martinelli, G ^l   Nielsen, J L ^m   Petersdorf, S ⁿ   Guilhot, F ^o   Barker, J ^p   Kirschmeier, P ^q   Frank, E ^q   Statkevich, P ^q   Zhu, Y ^q   Loechner, S ^q   List, A ^r   more..

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d GLASGOW ROYAL INFIRMARY   (United Kingdom)

^e UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^f NEWCASTLE UNIVERSITY   (United Kingdom)

^g INSTITUT BERGONIÉ   (France)

^h CROSS CANCER INSTITUTE   (Canada)

ⁱ PRINCESS MARGARET HOSPITAL   (Canada)

^j UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^k UNIVERSITY HOSPITAL OF TOURS   (France)

^l UNIVERSITY OF BOLOGNA   (Italy)

^m AARHUS UNIVERSITY HOSPITAL   (Denmark)

ⁿ SEATTLE CANCER CARE ALLIANCE   (United States)

^o POITIERS UNIVERSITY HOSPITAL   (France)

^p UNIVERSITY OF MINNESOTA   (United States)

^q MERCK RESEARCH LABORATORIES   (United States)

^r H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTIDIARRHEAL AGENT; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; APPETITE STIMULANT; ARSENIC TRIOXIDE; AZACITIDINE; CYTARABINE; CYTOTOXIC AGENT; HYDROXYUREA; LONAFARNIB; PROTEIN DERIVATIVE; PROTEIN FARNESYLTRANSFERASE; THALIDOMIDE;

ABDOMINAL PAIN; ADULT; AGED; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BONE MARROW BIOPSY; BONE MARROW SUPPRESSION; CHEMOTHERAPY INDUCED EMESIS; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DEHYDRATION; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FEVER; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; DYSPNEA; ENZYME MODIFICATION; FATIGUE; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN CELL; HYPOKALEMIA; LEUKEMIA REMISSION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MORNING DOSAGE; MULTICENTER STUDY; MYELODYSPLASTIC SYNDROME; NAUSEA; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN DETERMINATION; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH EXCESS BLASTS IN TRANSFORMATION; SIDE EFFECT; THROMBOCYTE TRANSFUSION; TIME TO MAXIMUM PLASMA CONCENTRATION; WEAKNESS; WEIGHT REDUCTION;

ADULT; AGED; AGED, 80 AND OVER; DRUG MONITORING; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; GASTROINTESTINAL DISEASES; HUMANS; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PIPERIDINES; PYRIDINES; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 51649113096     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2008.156     Document Type: Article

References (23)

1. Hofmann WK, Koeffler HP. Myelodysplastic syndrome. Annu Rev Med 2005; 56: 1-16.
2. Blinder VS, Roboz GJ. Hematopoietic growth factors in myelodysplastic syndromes. Curr Hematol Rep 2003; 2: 453-458.
3. List A, Kurtin S, Roe DJ, Buresh A, Mahadevan D, Fuchs D et al. Efficacy of lenalidomide in myelodysplastic syndromes. NEJM 2005; 352: 549-557.
4. Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimer-Reissig R et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B. J Clin Oncol 2002; 20: 2429-2440.
5. Rosenfeld C, List A. A hypothesis for the pathogenesis of myelodysplastic syndromes: Implications for new therapies. Leukemia 2000; 14: 2-8.
6. Clark GJ, Der CJ. Ras proto-oncogene activation in human malignancy. In Garrett CT, Sell S (eds). Cellular Cancer Markers, Vol. 1 Humana Press: Totowa, NJ, 1995, pp 17-52.
7. Paquette RL, Landaw EM, Pierre RV, Kahan J, Lubbert M, Lazcano O. N-ras mutations are associated with poor prognosis and increased risk of leukemia in myelodysplastic syndrome. Blood 1993; 82: 590-599.
8. Cogswell PC, Morgan R, Dunn M, Neubauer A, Nelson P, Poland-Johnston NK et al. Mutations of the ras protooncogenes in chronic myelogenous leukemia: A high frequency of ras mutations in bcr/abl rearrangement-negative chronic myelogenous leukemia. Blood 1989; 74: 2629-2633.
9. Lu D, Nounou R, Beran M, Estey E, Manshouri T, Kantarjian H et al. The prognostic significance of bone marrow levels of neurofibromatosis-1 protein and ras oncogene mutations in patients with acute myeloid leukemia and myelodysplastic syndrome. Cancer 2003; 97: 441-449.
10. Rowell CA, Kowalczyk JJ, Lewis MD, Garcia AM. Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo. Biol Chem 1997; 272: 14093-14097.
11. Ganguly AK, Doll RJ, Girijavallabhan VM. Farnesyl protein transferase inhibition: A novel approach to anti-tumor therapy. The discovery and development of SCH 66336. Curr Med Chem 2001; 8: 1419-1436.
12. Lebowitz PF, Prendergast GC. Non-Ras targets of farnesyltransferase inhibitors: Focus on Rho. Oncogene 1998; 17 (11 Reviews): 1439-1445.
13. Karp JE, Lancet JE, Kaufmann SH, End DW, Wright JJ, Bol K et al. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: A phase 1 clinical-laboratory correlative trial. Blood 2001; 97: 3361-3369.
14. Eskens FA, Awada A, Cutler DL, de Jonge MJ, Luyten GP, Faber MN et al Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors. J Clin Oncol 2001; 19: 1167-1175.
15. Khuri FR, Glisson BS, Kim ES, Statkevich P, Thall PF, Meyers ML et al Phase I study of the famesly transferase inhibitor lonafarnib with paclitaxel in solid tumors. Clin Cancer Res 2004; 10: 2968-2976.
16. List A, DeAngelo S, O'Brien S, Cortes J, Wilson J, Sugrue M et al. Phase I study of continuous oral lonafarnib in patients with advanced hematologic malignancies. Blood Suppl Dec 2002; 102(11); abstract 3120.
17. Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000; 96 3671-3674.
18. Britten CD, Rowinsky E, Soignet S, Patnaik A, Yao SL, Deutsch P et al A Phase I and Pharmacological Study of the Farnesyl Protein Transferase Inhibitor L-778, 123 in Patients with Solid Malignancies. Clin Cancer Res 2001; 7: 3894-3903.
19. Karp JE, Lancet JE. Development of the farnesyltransferase inhibitor tipifarnib for therapy of hematologic malignancies. Future Oncol 2005; 1: 719-731.
20. Kurzrock R, Kantarjian HM, Cortes JE, Singhania N, Thomas DA, Wilson EF et al. Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: Clinical and biologic activities in the phase 1 setting. Blood 2003; 102: 4527-4534. epub 2003 Aug 28.
21. Kurzrock R, Albitar M, Cortes JE, Estey EH, Faderl SH, Garcia-Manero G et al. Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome. J Clin Oncol 2004; 22 1287-1292.
22. Fenaux P, Raza A, Mufti GJ, Aul C, Germing U, Kantarjian H et al. A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate to high-risk myelodysplastic syndrome. Blood 2007; 109: 4158-4163.
23. Kurzrock R, Kantarjian H, Blascovich MA, Bucher C, Verstovesek S, Wright J et al. Phase I study using alternative week administration of the farnesyltransferase inhibitor R115777 (Zarnestra™) in patients with myelodysplastic syndrome. Clin Cancer Res 2008; 14: 509-514.